Asset Acquisition, Contingent Consideration, Current

No definition available.

Name:	dare_AssetAcquisitionContingentConsiderationCurrent
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Commencement Period For Stage Two Upon Achievement Of Stage One

+ References

No definition available.

+ Details

Name:	dare_CommencementPeriodForStageTwoUponAchievementOfStageOne
Namespace Prefix:	dare_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreement Notice Period Of Termination

+ References

No definition available.

+ Details

Name:	dare_LicenseAgreementNoticePeriodOfTermination
Namespace Prefix:	dare_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License agreement, termination period due to performance failure.

+ References

No definition available.

+ Details

Name:	dare_LicenseAgreementTerminationPeriodDueToPerformanceFailure
Namespace Prefix:	dare_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Agreement Termination Periodic Discontinued Sale Of Product

+ References

No definition available.

+ Details

Name:	dare_LicenseAgreementTerminationPeriodicDiscontinuedSaleOfProduct
Namespace Prefix:	dare_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

License Fee

+ References

No definition available.

+ Details

Name:	dare_LicenseFee
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License Fee, To Be Paid Upon Contingency

+ References

No definition available.

+ Details

Name:	dare_LicenseFeeToBePaidUponContingency
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum Potential Milestone Payments

+ References

No definition available.

+ Details

Name:	dare_MaximumPotentialMilestonePayments
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone Payments

+ References

No definition available.

+ Details

Name:	dare_MilestonePayments
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Milestone payments, contingent amount.

+ References

No definition available.

+ Details

Name:	dare_MilestonePaymentsContingentAmount
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Percentage of rights to inventions by employees under license agreement.

+ References

No definition available.

+ Details

Name:	dare_PercentageOfRightsToInventionsByEmployeesUnderLicenseAgreement
Namespace Prefix:	dare_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty rate.

+ References

No definition available.

+ Details

Name:	dare_PercentageOfRoyaltyRate
Namespace Prefix:	dare_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Potential Annual License Maintenance Fee, Payments In Year One

+ References

No definition available.

+ Details

Name:	dare_PotentialAnnualLicenseMaintenanceFeePaymentsInYearOne
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Potential Annual License Maintenance Fee Payments, Thereafter

+ References

No definition available.

+ Details

Name:	dare_PotentialAnnualLicenseMaintenanceFeePaymentsThereafter
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Research and development milestone payment.

+ References

No definition available.

+ Details

Name:	dare_ResearchAndDevelopmentMilestonePayment
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Upfront License Fee Paid

+ References

No definition available.

+ Details

Name:	dare_UpfrontLicenseFeePaid
Namespace Prefix:	dare_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of equity interests issued or issuable to acquire entity.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-URI http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479

+ Details

Name:	us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 924
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-URI http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_BusinessAcquisitionAxis=dare_MicrochipsBiotechInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ADVATecAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponAchievementOfSpecifiedDevelopmentAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_BayerHealthcareLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=dare_UponReachingCertainWorldwideNetSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_MilanaPharmMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_AssignmentAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_HammockPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_UponAchievingCertainClinicalAndRegulatoryDevelopmentMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_LicenseAndCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_StrategicScienceAndTechnologiesDLimitedLiabilityCompanyAndStrategicScienceTechnologiesLimitedLiabilityCompanyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_JuniperPharmaceuticalsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_ClinicalAndRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=dare_SalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=dare_DevelopmentAndOptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=dare_AdarePharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_UponSigningOfDevelopmentAndOptionAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_UponCompletionOfFiftyPercentDevelopmentNotLaterThanSixMonthsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionAxis=dare_UponDeliveryOfSixMonthBatchDevelopmentNotLaterThanElevenMonthsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements - Additional Information (Details) - USD ($)						1 Months Ended						3 Months Ended			9 Months Ended
	Jan. 31, 2020	Jan. 10, 2020	Dec. 05, 2019	Nov. 30, 2019	Nov. 20, 2019	Jan. 31, 2020	Dec. 31, 2019	Apr. 30, 2018	Mar. 31, 2018	Feb. 28, 2018	Mar. 31, 2017	Sep. 30, 2020	Jun. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License fee												$ 25,000		$ 133,333	$ 58,333	$ 408,333
Microchips Biotech, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Current portion of contingent consideration				$ 1,000,000.0	$ 1,000,000.0
Microchips Biotech, Inc. \| Common stock
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock issued to microchips capital stock holders (in shares)				2,999,990
Upon Achievement of Specified Development and Regulatory Milestones \| Microchips Biotech, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments					46,500,000
Current portion of contingent consideration					$ 55,000,000.0
ADVA Tec Agreement \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty rate											10.00%
ADVA Tec Agreement \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty rate											1.00%
ADVA Tec Agreement \| Upon Achievement of Specified Development and Regulatory Milestones \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments											$ 14,600,000
Bayer Healthcare License Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fee paid						$ 1,000,000.0
Revenue from grant for notice of award						$ 20,000,000.0
Milestone payments, contingent amount		$ 310,000,000.0
Licensing Agreements \| ADVA Tec Agreement \| Upon Reaching Certain Worldwide Net Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments											$ 20,000,000.0
Licensing Agreements \| MilanaPharm
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License fee							$ 25,000
License fee to be paid upon contingency	$ 110,000		$ 100,000
License agreement termination periodic discontinued sale of product			60 days
License agreement termination period due to performance failure			120 days
Certain clinical and regulatory development milestone payments			90 days
Licensing Agreements \| Upon Achieving Certain Development Milestones \| MilanaPharm \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount							$ 300,000
Licensing Agreements \| Upon Achieving Certain Commercial Milestones \| MilanaPharm
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount													$ 50,000
Licensing Agreements \| Upon Achieving Certain Commercial Milestones \| MilanaPharm \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount													$ 1,750,000
Assignment Agreement \| Hammock Pharmaceuticals, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License fee			$ 250,000
License fee to be paid upon contingency	$ 137,500		$ 125,000
Assignment Agreement \| Upon Achieving Certain Clinical and Regulatory Development Milestones \| Hammock Pharmaceuticals, Inc \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount															$ 1,100,000
Milestone Payments												$ 100,000
License and Collaboration Agreement \| Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of rights to inventions by employees under license agreement										50.00%
License and Collaboration Agreement \| Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount										$ 18,000,000.0
License and Collaboration Agreement \| Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount										500,000
License and Collaboration Agreement \| Upon Achieving Certain Commercial Milestones \| Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount										100,000,000.0
License and Collaboration Agreement \| Upon Achieving Certain Commercial Milestones \| Strategic Science and Technologies D Limited Liability Company and Strategic Science Technologies Limited Liability Company \| Minimum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments, contingent amount										$ 10,000,000.0
Juniper Pharmaceuticals, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fee paid								$ 250,000
Potential annual license maintenance fee, payments in year one								50,000
Potential annual license maintenance fee payments, thereafter								100,000
Juniper Pharmaceuticals, Inc \| Clinical and Regulatory Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments								13,500,000
Juniper Pharmaceuticals, Inc \| Sales Milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum potential milestone payments								$ 30,300,000
Development and Option Agreement \| Adare
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments									$ 300,000
Commencement period for stage two upon achievement of stage one									90 days
Development and Option Agreement \| Upon Signing of Development and Option Agreement \| Adare
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments									$ 150,000
Development and Option Agreement \| Upon Completion of Fifty Percent Development Not Later Than Six Months \| Adare
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments									$ 75,000
Percentage of rights to inventions by employees under license agreement									50.00%
Development and Option Agreement \| Upon Delivery of Six Month Batch Development Not Later Than Eleven Months \| Adare
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payments									$ 75,000